AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2016626 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients with pulmonary metastases
Number of subjects: 165
Study 6293296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils boiled for 20 min
Number of subjects: 8
Study 6293296 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended lentils to a paste
Number of subjects: 8
Study 6293296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils boiled for an additional 40 minutes
Number of subjects: 8
Study 6293296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried boiled blended lentils for 12 h at 250 degrees F
Number of subjects: 8
Study 6293296 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 8
Study 31323685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 84
Study 30999196 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA single dose
Number of subjects: 0
Study 30999196 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA two doses
Number of subjects: 0
Study 30999196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 27685009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 30
Study 27685009 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser plus water pressure massage
Number of subjects: 30
Study 27685009 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 30
Study 26242249 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Number of subjects: 794
Study 26242249 — intervention group
Group type: EXPERIMENTAL
Intervention: Uruguayan EQ-5D-5L value set
Number of subjects: 794
Study 26242249 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Argentinian EQ-5D-5L crosswalk value set
Number of subjects: 794
Study 26242249 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender analysis
Number of subjects: 794
Study 24346155 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before PCI
Number of subjects: 45
Study 24346155 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin preoperatively for 7 days
Number of subjects: 45
Study 24346155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 45
Study 21685819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 25 mL of plain water before and every 5 min (DR)
Number of subjects: 10
Study 21685819 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinse with 25 mL of plain water before and every 5 min (MR)
Number of subjects: 10
Study 21685819 — intervention group
Group type: COMPARATOR
Intervention: Control (CON), where no fluids were provided
Number of subjects: 10
Study 19614721 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with EMD
Number of subjects: 70
Study 19614721 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical access flap alone (Control)
Number of subjects: 70
Study 17241841 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling with optional advance EC prescription
Number of subjects: 737
Study 17241841 — intervention group
Group type: COMPARATOR
Intervention: No contraceptive or EC counseling
Number of subjects: 737
Study 15241771 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes at 75% Vo(2)max
Number of subjects: 12
Study 15241771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes at 75% Vo(2)max
Number of subjects: 12
Study 15241771 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes at 50% Vo(2)max
Number of subjects: 12
Study 12625668 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa 750‐4000 mg/day (n=34)
Number of subjects: 70
Study 12625668 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=36)
Number of subjects: 70
Study 10986365 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrated function
Number of subjects: 0
Study 10986365 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow response time
Number of subjects: 0
Study 10986365 — intervention group
Group type: EXPERIMENTAL
Intervention: Function consideration
Number of subjects: 0
Study 10986365 — intervention group
Group type: COMPARATOR
Intervention: Lexical and non-lexical conditions
Number of subjects: 0
Study 8829020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 91
Study 8829020 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate 40 mg sustained-release
Number of subjects: 91
Study 1452083 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 92
Study 1452083 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal transection and gastric devascularisation
Number of subjects: 92
Study 6710092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training with follow-up control of results
Number of subjects: 20
Study 6710092 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 20
Study 30982761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Number of subjects: 131
Study 30982761 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Number of subjects: 131
Study 30024924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 160
Study 30024924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 27461399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 80
Study 27461399 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular aripiprazole
Number of subjects: 80
Study 27461399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 23904470 — intervention group
Group type: EXPERIMENTAL
Intervention: Early MRI measures (baseline and changes at weeks 12 and 24)
Number of subjects: 256
Study 23904470 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models incorporating baseline and 12-week and 24-week changes in MRI measures
Number of subjects: 256
Study 22685559 — intervention group
Group type: EXPERIMENTAL
Intervention: PINCER intervention
Number of subjects: 0
Study 20055763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/ml
Number of subjects: 16
Study 20055763 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 18726957 — intervention group
Group type: COMPARATOR
Intervention: 5 ml lidocaine (group L)
Number of subjects: 84
Study 18726957 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml lidocaine + 0.5 mg dinitrate isosorbide (group LN)
Number of subjects: 84
Study 15735447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0
Study 15735447 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study 15735447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine + Efavirenz (NVP + EFV)
Number of subjects: 0
Study 15735447 — intervention group
Group type: COMPARATOR
Intervention: Baseline pVL >100,000 copies/mL
Number of subjects: 0
Study 15735447 — intervention group
Group type: COMPARATOR
Intervention: High VDc
Number of subjects: 0
Study 12562741 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT) for 12 months
Number of subjects: 58
Study 12562741 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 58
Study 10567276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary autograft
Number of subjects: 25
Study 10567276 — intervention group
Group type: COMPARATOR
Intervention: Aortic homograft
Number of subjects: 25
Study 10567276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (homografts and autografts)
Number of subjects: 25
Study 8764554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 25
Study 1925058 — intervention group
Group type: EXPERIMENTAL
Intervention: Different distance group (20 degrees left hand, 60 degrees right hand)
Number of subjects: 60
Study 1925058 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (20 degrees in each limb)
Number of subjects: 60
Study 29490675 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by village doctors
Number of subjects: 28
Study 29490675 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program
Number of subjects: 28
Study 27471314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 µg·kg(‐1)
Number of subjects: 75
Study 27471314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 µg·kg(‐1) and ketamine 1 mg·kg(‐1)
Number of subjects: 75
Study 27471314 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 75
Study 24864045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher heart rate in patients in sinus rhythm (categorical and continuous analysis)
Number of subjects: 3967
Study 24864045 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker treatment
Number of subjects: 3967
Study 24864045 — intervention group
Group type: COMPARATOR
Intervention: Heart rate in patients in atrial fibrillation
Number of subjects: 3967
Study 22266895 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral clarithromycin twice daily for 5 months
Number of subjects: 63
Study 22266895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20452258 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany (SE)
Number of subjects: 100
Study 20452258 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH‐Plus
Number of subjects: 100
Study 18039954 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 450 mg orally twice daily
Number of subjects: 40
Study 18039954 — intervention group
Group type: COMPARATOR
Intervention: Valaciclovir 500 mg orally daily
Number of subjects: 40
Study 16046717 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood development (ECD) intervention
Number of subjects: 313
Study 16046717 — intervention group
Group type: COMPARATOR
Intervention: Nutrition intervention
Number of subjects: 313
Study 12126385 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocodone/1000 mg of acetaminophen
Number of subjects: 15
Study 12126385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9891150 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent study of resident-prepared chest radiology teaching cases
Number of subjects: 65
Study 9891150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no independent study)
Number of subjects: 65
Study 7741785 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Analgin) containing 1 g of metamizole
Number of subjects: 12
Study 7741785 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation containing 1 g of metamizole
Number of subjects: 12
Study 7741785 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Analgin)
Number of subjects: 12
Study 7741785 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12
Study 7741785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study 1904450 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg single dose of melatonin
Number of subjects: 11
Study 1904450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg melatonin in three divided doses (1 mg at 0800 hrs., 0.75 mg at 1000 and 1200 hrs.)
Number of subjects: 11
Study 1904450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6752050 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance with 3-day attendance schedule
Number of subjects: 95
Study 6752050 — intervention group
Group type: COMPARATOR
Intervention: LAAM maintenance
Number of subjects: 95
Study 6752050 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 95
Study 6752050 — intervention group
Group type: COMPARATOR
Intervention: LAAM maintenance with 3-day attendance schedule
Number of subjects: 95
Study 30446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) (FA, Fe 30 mg)
Number of subjects: 18775
Study 30446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN) (FA, Fe and 13 micronutrients)
Number of subjects: 18775
Study 30446762 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone (FA) (400 μg)
Number of subjects: 18775
Study 30446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA)
Number of subjects: 18775
Study 30446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN)
Number of subjects: 18775
Study 30446762 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone (FA)
Number of subjects: 18775
Study 28872913 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 0
Study 28872913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26923418 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the left lateral prefrontal cortex during learning phase.
Number of subjects: 0
Study 26923418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) tDCS during learning phase.
Number of subjects: 0
Study 24590734 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention (PCPs received skills training and standardized patient feedback on counseling behaviors)
Number of subjects: 168
Study 24590734 — intervention group
Group type: COMPARATOR
Intervention: Audit-feedback (PCPs received clinical performance feedback)
Number of subjects: 168
Study 24590734 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention
Number of subjects: 168
Study 22516321 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Invigor8 (Internet-based cognitive behavioural therapy self-management programme)
Number of subjects: 40
Study 22516321 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 19681418 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 19681418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 19681418 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 16385545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 75
Study 16385545 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 75
Study 16385545 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 75
Study 14525749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate pain control
Number of subjects: 143
Study 14525749 — intervention group
Group type: COMPARATOR
Intervention: Inadequate pain control
Number of subjects: 143
Study 14525749 — intervention group
Group type: EXPERIMENTAL
Intervention: Any analgesics accepted
Number of subjects: 143
Study 14525749 — intervention group
Group type: COMPARATOR
Intervention: No analgesic need
Number of subjects: 143
Study 14525749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral analgesics accepted
Number of subjects: 143
Study 11020621 — intervention group
Group type: EXPERIMENTAL
Intervention: Array(R) foldable multifocal IOL (model SA‐40N, Allergan)
Number of subjects: 124
Study 11020621 — intervention group
Group type: COMPARATOR
Intervention: AMO(R) PhacoFlex II(R) silicone monofocal IOL (model SI‐40NB)
Number of subjects: 124
Study 8866535 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Evaluation System (NES) tests
Number of subjects: 0
Study 8866535 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuropsychological tests
Number of subjects: 0
Study 1738969 — intervention group
Group type: EXPERIMENTAL
Intervention: Uppsala screws
Number of subjects: 179
Study 1738969 — intervention group
Group type: COMPARATOR
Intervention: Hansson pins
Number of subjects: 179
Study 6337982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled atropine (0.5 mg)
Number of subjects: 6
Study 6337982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine (0.5 mg)
Number of subjects: 6
Study 6337982 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 6
Study 6337982 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 6
Study 6337982 — intervention group
Group type: COMPARATOR
Intervention: Inhaled and intravenous placebos
Number of subjects: 6
Study 31507054 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (specific dosage and duration not mentioned)
Number of subjects: 0
Study 31507054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent statin dosing, new LDL-lowering drugs, LDL apheresis, and supplements (specific details not mentioned)
Number of subjects: 0
Study 28118323 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (weekly paclitaxel 80 mg/m² or four weekly pegylated liposomal doxorubicin 40 mg/m²)
Number of subjects: 238
Study 28118323 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (40 mg daily)
Number of subjects: 238
Study 25290597 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention for obesity prevention
Number of subjects: 294
Study 23902483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 119
Study 21763893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 22
Study 21763893 — intervention group
Group type: COMPARATOR
Intervention: Ultracal XS
Number of subjects: 22
Study 19447919 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg/d
Number of subjects: 24
Study 19447919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16527576 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (six weekly instillations of 80 mg BCG [Tokyo 172 strain])
Number of subjects: 80
Study 16527576 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (17 instillations of 20 mg doxorubicin)
Number of subjects: 80
Study 15471823 — intervention group
Group type: EXPERIMENTAL
Intervention: NOGA mapping of endocardial unipolar voltage
Number of subjects: 21
Study 15471823 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Number of subjects: 21
Study 15471823 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl SPECT
Number of subjects: 21
Study 11133606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg IV
Number of subjects: 80
Study 11133606 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 9753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin once a day with ticarcillin-clavulanate (TC)
Number of subjects: 249
Study 9753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin three times a day with ticarcillin-clavulanate (TC)
Number of subjects: 249
Study 9753020 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin-clavulanate (TC) alone
Number of subjects: 249
Study 7790757 — intervention group
Group type: EXPERIMENTAL
Intervention: trapidil 200 mg tablets bid
Number of subjects: 30
Study 7790757 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 2899451 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion at a dose rate of 80 +/- 59 micrograms/kg/min
Number of subjects: 48
Study 2899451 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 48
Study 28885667 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal intraocular lens (IOL) implantation (FineVision and AT LISA tri 839MP)
Number of subjects: 50
Study 26588810 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) therapy with subcutaneous insulin via CL pump (n = 7)
Number of subjects: 14
Study 26588810 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections with blinded continuous glucose monitor (CGM) (n = 7)
Number of subjects: 14
Study 25623207 — intervention group
Group type: EXPERIMENTAL
Intervention: High achievement orientation
Number of subjects: 155
Study 25623207 — intervention group
Group type: COMPARATOR
Intervention: Low achievement orientation
Number of subjects: 155
Study 25623207 — intervention group
Group type: EXPERIMENTAL
Intervention: High social orientation
Number of subjects: 155
Study 25623207 — intervention group
Group type: COMPARATOR
Intervention: Low social orientation
Number of subjects: 155
Study 23363373 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactagogue herbal tea (Humana still-tee®, Herford, Deutschland) 3 cups/d
Number of subjects: 80
Study 23363373 — intervention group
Group type: COMPARATOR
Intervention: Water as placebo (3 cups/d)
Number of subjects: 80
Study 21094848 — intervention group
Group type: EXPERIMENTAL
Intervention: Equoral
Number of subjects: 30
Study 21094848 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 30
Study 21094848 — intervention group
Group type: COMPARATOR
Intervention: Both Equoral and Neoral
Number of subjects: 30
Study 19006503 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg daily)
Number of subjects: 20
Study 19006503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 31
Study 17213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 31
Study 17213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (older group)
Number of subjects: 31
Study 17213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 31
Study 17213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability assessment
Number of subjects: 31
Study 12617376 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐plant extracts of delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 24
Study 12617376 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐plant extracts of cannabidiol (CBD)
Number of subjects: 24